中国肝静脉压力梯度临床应用专家共识(2018版)

中国门静脉高压诊断与监测研究组(CHESS); 中华医学会消化病学分会微创介入协作组; 中国医师协会介入医师分会急诊介入专业委员会; 中华医学会消化病学分会肝胆疾病协作组; 中华医学会外科学分会脾脏及门静脉高压学组; 中华医学会肝病学分会脂肪肝和酒精性肝病学组; 中国研究型医院学会肝病专业委员会; 中华预防医学会肝胆胰疾病预防与控制专业委员会; 中华医学会数字医学分会; 中华医学会临床流行病学和循证医学分会

doi:10.3969/j.issn.1001-5256.2018.12.008

中国肝静脉压力梯度临床应用专家共识(2018版)

DOI: 10.3969/j.issn.1001-5256.2018.12.008

详细信息

中图分类号: R575.2
计量
- 文章访问数: 446
- HTML全文浏览量: 18
- PDF下载量: 307
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Consensus on clinical application of hepatic venous pressure gradient in China (2018)

摘要

- 高血压,门静脉 /
- 肝静脉压力梯度 /
- 中国 /
- 共识
- hypertension, portal /
- hepatic venous pressure gradient /
- China /
- consensus

HTML全文

参考文献(102)

[1] QI X, BERZIGOTTI A, CARDENAS A, et al. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension[J]. Lancet Gastroenterol Hepatol, 2018, 3 (10) :708-719.

[2] BOSCH J, ABRALDES JG, BERZIGOTTI A, et al. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol, 2009, 6 (10) :573-582.

[3] WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease:The major impact of China[J]. Hepatology, 2014, 60 (6) :2099-2108.

[4] MOKDAD AA, LOPEZ AD, SHAHRAZ S, et al. Liver cirrhosis mortality in 187 countries between1980 and 2010:A systematic analysis[J]. BMC Medicine, 2014, 12:145.

[5] ESTES C, ANSTEE QM, TERESA ARIAS-LOSTE M, et al.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018.[Epub ahead of print]

[6] WANG X, LIN SX, TAO J, et al. Study of liver cirrhosis over ten consecutive years in Southern China[J]. World J Gastroenterol, 2014, 20 (37) :13546-13555.

[7] GROSZMANN RJ, WONGCHARATRAWEE S. The hepatic venous pressure gradient:Anything worth doing should be done right[J]. Hepatology, 2004, 39 (2) :280-282.

[8] ABRALDES JG, SARLIEVE P, TANDON P. Measurement of portal pressure[J]. Clin Liver Dis, 2014, 18 (4) :779-792.

[9] de FRANCHIS R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol, 2005, 43 (1) :167-176.

[10] de FRANCHIS R; Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[11] GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis:Risk stratification, diagnosis, and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65 (1) :310-335.

[12] MERKEL C, MONTAGNESE S. Hepatic venous pressure gradient measurement in clinical hepatology[J]. Digest Liver Dis, 2011, 43 (10) :762-767.

[13] TEY TT, GOGNA A, IRANI FG, et al. Application of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhotics[J]. Singapore Med J, 2016, 57 (3) :132-137.

[14] WANG JY, WANG Q, WANG XQ, et al. Establishment and preliminary validation of the evaluation system for clinical practice guidelines in China[J]. Natl Med J China, 2018, 98 (20) :1544-1548. (in Chinese) 王吉耀, 王强, 王小钦, 等.中国临床实践指南评价体系的制定与初步验证[J].中华医学杂志, 2018, 98 (20) :1544-1548.

[15] GUYATT GH, OXMAN AD, VIST GE, et al. GRADE:An emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336 (7650) :924-926.

[16] BALSHEM H, HELFAND M, SCHüNEMANN HJ, et al. GRADE guidelines:3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64 (4) :401-406.

[17] GUYATT GH, OXMAN AD, SCHüNEMANN HJ, et al. GRADE guidelines:A new series of articles in the Journal of Clinical Epidemiology[J]. J Clin Epidemiol, 2011, 64 (4) :380-382.

[18] GUYATT GH, OXMAN AD, VIST G, et al. GRADE guidelines:4.Rating the quality of evidence-study limitations (risk of bias) [J]. J Clin Epidemiol, 2011, 64 (4) :407-415.

[19] GUYATT GH, OXMAN AD, MONTORI V, et al. GRADE guidelines:5. Rating the quality of evidence-publication bias[J]. J Clin Epidemiol, 2011, 64 (12) :1277-1282.

[20] GUYATT GH, OXMAN AD, KUNZ R, et al. GRADE guidelines:6.Rating the quality of evidence-imprecision[J]. J Clin Epidemiol, 2011, 64 (12) :1283-1293.

[21] GUYATT GH, OXMAN AD, KUNZ R, et al. GRADE guidelines:7.Rating the quality of evidence-inconsistency[J]. J Clin Epidemiol, 2011, 64 (12) :1294-1302.

[22] GUYATT GH, OXMAN AD, KUNZ R, et al. GRADE guidelines:8.Rating the quality of evidence-indirectness[J]. J Clin Epidemiol, 2011, 64 (12) :1303-1310.

[23] MURPHY MK, BLACK NA, LAMPING DL, et al. Consensus development methods, and their use in clinical guideline development[J]. Health Technol Assess, 1998, 2 (3) :i-iv, 1-88.

[24] BLASCO A, FORNS X, CARRIN JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation[J]. Hepatology, 2006, 43 (3) :492-499.

[25] GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al. Betablockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005, 353 (21) :2254-2261.

[26] RIPOLL C, GROSZMANN R, GARCIA-TSAO G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007, 133 (2) :481-488.

[27] RIPOLL C, GROSZMANN RJ, GARCIA-TSAO G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis[J]. J Hepatol, 2009, 50 (5) :923-928.

[28] BRUIX J, CASTELLS A, BOSCH J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients:Prognostic value of preoperative portal pressure[J]. Gastroenterology, 1996, 111 (4) :1018-1022.

[29] BOLESLAWSKI E, PETROVAI G, TRUANT S, et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis[J]. Br J Surg, 2012, 99 (6) :855-863.

[30] LLOP E, BERZIGOTTI A, REIG M, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors[J]. J Hepatol, 2012, 56 (1) :103-108.

[31] CUCCHETTI A, CESCON M, GOLFIERI R, et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma[J]. J Hepatol, 2016, 64 (1) :79-86.

[32] BERZIGOTTI A, REIG M, ABRALDES JG, et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis:A systematic review and meta-analysis[J].Hepatology, 2015, 61 (2) :526-536.

[33] GARCIA-TSAO G, GROSZMANN RJ, FISHER RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding[J]. Hepatology, 1985, 5 (3) :419-424.

[34] KERBERT AJ, CHIANG FW, van der WERF M, et al. Hemodynamic response to primary prophylactic therapy with nonselectiveβ-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis:A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2017, 29 (4) :380-387.

[35] MERKEL C, BOLOGNESI M, BELLON S, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices[J]. Gastroenterology, 1992, 102 (3) :973-979.

[36] MERKEL C, BOLOGNESI M, SACERDOTI D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis[J]. Hepatology, 2000, 32 (5) :930-934.

[37] SILVA-JUNIOR G, BAIGES A, TURON F, et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique[J]. Hepatology, 2015, 62 (5) :1584-92.

[38] BERZIGOTTI A, ROSSI V, TIANI C, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension[J]. J Gastroenterol, 2011, 46 (5) :687-695.

[39] MOITINHO E, ESCORSELL A, BANDI JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding[J]. Gastroenterology, 1999, 117 (3) :626-631.

[40] MONESCILLO A, MARTNEZ-LAGARES F, RUIZ-DEL-ARBOL L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding[J].Hepatology, 2004, 40 (4) :793-801.

[41] ZHAO JR, WANG GC, HU JH, et al. Risk factors for early rebleeding and mortality in acute variceal hemorrhage[J]. World J Gastroenterol, 2014, 20 (47) :17941-17948.

[42] RINCON D, LO IACONO O, RIPOLL C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis[J]. Aliment Pharmacol Ther, 2007, 25 (7) :841-848.

[43] SCHWARZER R, KIVARANOVIC D, PATERNOSTRO R, et al.Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding:A dose-response study[J]. Aliment Pharmacol Ther, 2018, 47 (8) :1162-1169.

[44] VILLANUEVA C, ARACIL C, COLOMO A, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding[J]. Gastroenterology, 2009, 137 (1) :119-128.

[45] HERNDEZ-GEA V, ARACIL C, COLOMO A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers[J]. Am J Gastroenterol, 2012, 107 (3) :418-427.

[46] QI XS, FAN DM. Hepatic venous pressure gradient measurement before TIPS for acute variceal bleeding[J]. World J Gastroenterol, 2014, 20 (23) :7523-7524.

[47] GARCA-PAGN JC, CACA K, BUREAU C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding[J]. N Engl J Med, 2010, 362 (25) :2370-2379.

[48] ZHANG M, WANG G, ZHAO L, et al. Second prophylaxis of variceal bleeding in cirrhotic patients with a high HVPG[J]. Scand J Gastroenterol, 2016, 51 (12) :1502-1506.

[49] D'AMICO G, GARCIA-PAGAN JC, LUCA A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis:A systematic review[J]. Gastroenterology, 2006, 131 (5) :1611-24.

[50] VILLANUEVA C, GRAUPERA I, ARACIL C, et al. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis[J]. Hepatology, 2017, 65 (5) :1693-1707.

[51] ZHANG MY, WANG GC, HUANG GJ, et al. Analysis of 833times measured hepatic venous pressure gradient[J]. Chin J Hepatol, 2018, 26 (4) :266-270. (in Chinese) 张明艳, 王广川, 黄广军, 等. 833例次肝静脉压力梯度测定临床分析[J].中华肝脏病杂志, 2018, 26 (4) :266-270.

[52] BAIK SK, JEONG PH, JI SW, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis:A randomized comparison[J]. Am J Gastroenterol, 2005, 100 (3) :631-635.

[53] LIM YL, KIM MY, JANG YO, et al. Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure:An open randomized controlled pilot study[J]. Gut Liver, 2017, 11 (5) :702-710.

[54] SCHWARZER R, KIVARANOVIC D, MANDORFER M, et al.Randomised clinical study:The effects of oral taurine 6g/day vs placebo on portal hypertension[J]. Aliment Pharmacol Ther, 2018, 47 (1) :86-94.

[55] GARCIA-TSAO G, FUCHS M, SHIFFMAN M, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension[J]. Hepatology, 2018.[Epub ahead of print]

[56] RATZIU V, GOODMAN Z, SANYAL A. Current efforts and trends in the treatment of NASH[J]. J Hepatol, 2015, 62 (Suppl 1) :s65-s75.

[57] WONG VW, ADAMS LA, de LDINGHEN V, et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise[J]. Nat Rev Gastroenterol Hepatol, 2018, 15 (8) :461-478.

[58] SOURIANARAYANANE A, TALLURI J, HUMAR A, et al. Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis[J]. Eur J Gastroenterol Hepatol, 2017, 29 (5) :516-523.

[59] SANYAL AJ1, FRIEDMAN SL, MCCULLOUGH AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:Findings and recommendations from an American Association for the Study of Liver Diseases-U. S. Food and Drug Administration Joint Workshop[J]. Hepatology, 2015, 61 (4) :1392-1405.

[60] HARRISON SA, ABDELMALEK MF, CALDWELL S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, S0016-5085 (18) :34758-34759.

[61] TRIPATHI D, STANLEY AJ, HAYES PC, et al. U. K. guidelines on the management of variceal haemorrhage in cirrhotic patients[J].Gut, 2015, 64 (11) :1680-1704.

[62] QI XL. Cirrhotic portal hypertension in the non-invasive era:what we grasp[J]. Chin J Hepatol, 2018, 26 (4) :241-244. (in Chinese) 祁小龙.肝硬化门静脉高压无创时代:我们如何把握[J].中华肝脏病杂志, 2018, 26 (4) :241-244.

[63] FERLITSCH M, REIBERGER T, HOKE M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis[J]. Hepatology, 2012, 56 (4) :1439-1447.

[64] HAMETNER S, FERLITSCH A, FERLITSCH M, et al. The VITRO score (von willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non-invasive parameters of fibrosis including ELF test[J]. PLo S One, 2016, 11 (2) :e0149230.

[65] SANDAHL TD, MCGRAIL R, MLLER HJ, et al. The macrophage activation marker s CD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2016, 43 (11) :1222-1231.

[66] PIND ML, BENDTSEN F, KALLEMOSE T, et al. Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis[J]. Eur J Gastroenterol Hepatol, 2016, 28 (8) :948-954.

[67] WANG L, FENG Y, MA X, et al. Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis[J]. PLo S One, 2017, 12 (8) :e0182969.

[68] MANDORFER M, SCHEINER B, STTTERMAYER AF, et al.Impact of patatin-like phospholipase domain containing 3rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension[J]. Aliment Pharmacol Ther, 2018.[Epub ahead of print]

[69] LEEMING DJ, VEIDAL SS, KARSDAL MA, et al. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis[J].Scand J Gastroenterol, 2015, 50 (5) :584-592.

[70] BRUHA R, JACHYMOVA M, PETRTYL J, et al. Osteopontin:A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis[J]. World J Gastroenterol, 2016, 22 (12) :3441-3450.

[71] YOU MW, KIM KW, PYO J, et al. A Meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension[J]. Ultrasound Med Biol, 2016, 43 (1) :59-68.

[72] BERZIGOTTI A. Non-invasive evaluation of portal hypertension using ultrasound elastography[J]. J Hepatol, 2017, 67 (2) :399-411.

[73] ATTIA D, SCHOENEMEIER B, RODT T, et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension[J]. Ultraschall Med, 2015, 36 (6) :603-610.

[74] DENG H, QI X, ZHANG T, et al. Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases:A meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2017, 12 (1) :91-98.

[75] THIELE M, MADSEN BS, PROCOPET B, et al. Reliability criteria for liver stiffness measurements with real-time 2d shear wave elastography in different clinical scenarios of chronic liver disease[J]. Ultraschall Med, 2017, 38 (6) :648-654.

[76] PROCOPET B, BERZIGOTTI A, ABRALDES JG, et al. Realtime shear-wave elastography:Applicability, reliability and accuracy for clinically significant portal hypertension[J]. J Hepatol, 2015, 62 (5) :1068-1075.

[77] SONG J, HUANG J, HUANG H, et al. Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension:A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2018, 42 (3) :216-226.

[78] TAKUMA Y, NOUSO K, MORIMOTO Y, et al. Portal Hypertension in patients with liver cirrhosis:Diagnostic accuracy of spleen stiffness[J]. Radiology, 2016, 279 (2) :609-619.

[79] ZYKUS R, JONAITIS L, PETRENKIEN E·V, et al. Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease:A prospective cohort study[J]. BMC Gastroenterol, 2015, 24:183.

[80] ELKRIEF L, RAUTOU PE, RONOT M, et al. Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis[J]. Radiology, 2015, 275 (2) :589-598.

[81] JANSEN C, BOGS C, VERLINDEN W, et al. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension:A prospective multicentre study[J]. Liver Int, 2017, 37 (3) :396-405.

[82] ELKRIEF L, RONOT M, ANDRADE F, et al. Non-invasive evaluation of portal hypertension using shear-wave elastography:Analysis of two algorithms combining liver and spleen stiffness in 191patients with cirrhosis[J]. Aliment Pharmacol Ther, 2018, 47 (5) :621-630.

[83] SONG J, MA Z, HUANG J, et al. Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases:A meta-analysis[J]. Eur Radiol, 2018.[Epub ahead of print]

[84] PIECHA F, MANDORFER M, PECCERELLA T, et al. Pharmacological decrease of liver stiffness is pressure-related and predicts long term clinical outcome[J]. Am J Physiol Gastrointest Liver Physiol, 2018.[Epub ahead of print]

[85] LIU F, NING Z, LIU Y, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701) :A prospective multicenter study[J]. EBioMedicine, 2018.[Epub ahead of print]

[86] PALANIYAPPAN N, COX E, BRADLEY C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol, 2016, 65 (6) :1131-1139.

[87] CHOUHAN MD, MOOKERJEE RP, BAINBRIDGE A, et al. Caval subtraction 2D phase-contrast MRI to measure total liver and hepatic arterial blood flow:Proof-of-principle, correlation with portal hypertension severity and validation in patients with chronic liver disease[J]. Invest Radiol, 2017, 52 (3) :170-176.

[88] GHARIB AM, HAN MAT, MEISSNER EG, et al. Magnetic resonance elastography shear wave velocity correlates with liver fibrosis and hepatic venous pressure gradient in adults with advanced liver disease[J]. Biomed Res Int, 2017, 2017:2067479.

[89] QI X, LI Z, HUANG J, et al. Virtual portal pressure gradient from anatomic CT angiography[J]. Gut, 2015, 64 (6) :1004-1005.

[90] LEE DH, AHN JH, CHUNG JW, et al. Varices on CT is surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patient[J]. J Gastroenterol Hepatol, 2018.[Epub ahead of print]

[91] KIM MY, BAIK SK, PARK DH, et al. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis:A prospective nonrandomized study[J]. Liver Int, 2007, 27 (8) :1103-1110.

[92] BOLOGNESI M, SACERDOTI D, MERKEL C, et al. Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler[J]. Ultrasound Med Biol, 2001, 27 (7) :901-907.

[93] LEE CM, JEONG WK, LIM S, et al. Diagnosis of clinically significant portal hypertension in patients with cirrhosis:Splenic arterial resistive index versus liver stiffness measurement[J]. Ultrasound Med Biol, 2016, 42 (6) :1312-1320.

[94] MARUYAMA H, YOKOSUKA O. Ultrasonography for noninvasive assessment of portal hypertension[J]. Gut Liver, 2017, 11 (4) :464-473.

[95] MARUYAMA H, SHIHA G, YOKOSUKA O, et al. Non-invasive assessment of portal hypertension and liver fibrosis using contrastenhanced ultrasonography[J]. Hepatol Int, 2016, 10 (2) :267-276.

[96] EISENBREY JR, DAVE JK, HALLDORSDOTTIR VG, et al. Chronic liver disease:Noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient[J]. Radiology, 2013, 268 (2) :581-588.

[97] AMAT-ROLDAN I, BERZIGOTTI A, GILABERT R, et al. Assessment of hepatic vascular network connectivity with automated graph analysis of dynamic contrast-enhanced US to evaluate portal hypertension in patients with cirrhosis:A pilot study[J]. Radiology, 2015, 277 (1) :268-276.

[98] BERZIGOTTI A, PISCAGLIA F, AMAT-ROLDAN I, et al. Noninvasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound:The CLEVER study[J]. J Hepatol, 2018, 68:s76-s77.

[99] TALAKIC'E, SCHAFFELLNER S, KNIEPEISS D, et al. CT perfusion imaging of the liver and the spleen in patients with cirrhosis:Is there a correlation between perfusion and portal venous hypertension[J]. Eur Radiol, 2017, 27 (10) :4173-4180.

[100] ASENBAUM U, BA-SSALAMAH A, MANDORFER M, et al.Effects of portal hypertension on gadoxetic acid-enhanced liver magnetic resonance:Diagnostic and prognostic implications[J]. Invest Radiol, 2017, 52 (8) :462-469.

[101] LIU J, ZHANG H, XIA Y, et al. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma:A systematic review and meta-analysis[J]. HPB (Oxford) , 2018.[Epub ahead of print]

[102] LIM C, OSSEIS M, LAHAT E, et al. Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension:interim analysis of an open prospective study[J]. Surg Endosc, 2018.[Epub ahead of print]

施引文献

资源附件(0)

访问统计